Peptide-based condensates for modulating chemical transformations

Peptide-based condensates address the challenge of reacting hydrophobic components in aqueous environments by encapsulating reactants for efficient chemical reactions and simplified purification, enhancing the production of antibody-drug conjugates.

WO2026234663A1PCT designated stage Publication Date: 2026-11-12RAMOT AT TEL AVIV UNIVERSITY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050366
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-09-21
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently encapsulate and react hydrophobic components in aqueous environments without the need for organic solvents, limiting the effectiveness of chemical reactions and complicating the production of antibody-drug conjugates.

Method used

Peptide-based condensates are designed to encapsulate hydrophobic reactants through liquid-liquid phase separation, using peptides with GX or XG dyads, aromatic amino acids, and aliphatic residues, enabling CuAAC reactions in an aqueous buffer with minimal organic solvent, and allowing for efficient production of antibody-drug conjugates.

Benefits of technology

The peptide-based condensates enhance reaction efficiency and product localization, simplify purification by separating copper ions, and achieve homogeneous antibody-drug conjugates with controlled drug-antibody ratios.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2026050366_12112026_PF_FP_ABST
    Figure IL2026050366_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to aqueous compositions including peptide-based condensates in an aqueous buffer, the condensates including a peptide including at least one GX or XG dyad, at least one aromatic amino acid, and a total of 0-2 aliphatic residues, wherein G is glycine, and X is selected from arginine, lysine, Glutamic acid, and aspartic acid; and reagents for a CuAAC reaction including an azide-containing compound, an alkyne-containing compound, and a copper salt. The CuAAC reaction may specifically be used for producing antibody-drug conjugates (ADC)s by using an monoclonal antibody (mAb) and a drug wherein one is conjugated to an azide- containing compound and the other is conjugated to an alkyne-containing compound. The present invention further provides methods for conducting CuAAC reactions in the aqueous compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PEPTIDE-BASED CONDENSATES FOR MODULATING CHEMICAL TRANSFORMATIONS

[0002] The project leading to this application has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 101162920).

[0003] FIELD OF THE INVENTION

[0004] The present invention is generally directed to peptide-based condensates for carrying out chemical reactions. More specifically, the invention relates to peptide-based condensates for carrying out chemical reactions involving hydrophobic reactants in an aqueous environment. In more specific embodiments, the present invention relates to peptide-based condensates for the preparation of antibody-drug conjugates.

[0005] BACKGROUND OF THE INVENTION

[0006] The compartmentalization of biochemical reactions within spatially distinct cellular environments is a hallmark of life, allowing for precise spatiotemporal regulation of complex processes. For example, ATP synthesis occurs within mitochondria, leveraging the proton gradient to drive energy production, while proteolysis is compartmentalized in lysosomes, isolating degradative enzymes to ensure cellular homeostasis. Beyond membrane-bound organelles, many cellular functions are orchestrated within membraneless organelles, or biomolecular condensates, which are formed through liquid-liquid phase separation (LLPS) and provide dynamic, compartmentalized environments for biochemical transformations. Such condensates, including nucleoli and nuclear stress bodies, create specialized microenvironments for processes like ribosome assembly and phosphorylation of splicing factors, respectively.

[0007] The physical basis of LLPS lies in networks of weak, non-covalent interactions among intrinsically disordered proteins (IDPs) and nucleic acids, including electrostatic interactions, hydrogen bonds, and n- it stacking. This interplay of interactions generates dense, liquid-like phases with unique physicochemical properties, which enable the selective recruitment, sequestration, and transformation of biomolecules. These features have inspired the design of synthetic biomolecular condensates. However, despite the potential of synthetic condensates, understanding the determinants that govern their performance as reaction vessels — particularly how dense-phase chemical properties affect reactant recruitment, reaction efficiency, and product localization, is important for designing of a condensate that can efficiently recruit hydrophobicreactants and mediate reactions in aqueous systems, avoiding or limiting the need for organic solvents.

[0008] Accordingly, there is a need for design of peptide-based condensates capable of efficiently supporting reactions involving hydrophobic components in aqueous environments, capable of encapsulating hydrophobic reactants while keeping their reactivity.

[0009] SUMMARY OF INVENTION

[0010] The following embodiments are described and illustrated in conjunction with compositions and methods which are meant to be exemplary and illustrative, not limiting in scope. In various embodiments, one or more of the above-described problems have been reduced or eliminated, while other embodiments are directed to other advantages or improvements.

[0011] In some embodiments, there is provided an aqueous composition including a peptide-based condensate in an aqueous buffer, the condensate including:

[0012] a peptide including: at least one GX or XG dyad, at least one aromatic amino acid, and 0- 2 aliphatic residues; and

[0013] reagents for a CuAAC reaction including an azide-containing compound, an alkyne- containing compound, and a copper salt,

[0014] wherein:

[0015] the G in the GX or XG dyad is glycine;

[0016] the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid; and

[0017] the CuAAC reagents are at least partially encapsulated within the condensate.

[0018] In some embodiments, the composition includes less than 10% of an organic solvent. In some embodiments, the organic solvent is tert-butanol. In some embodiments, the composition does not include an organic solvent.

[0019] In some embodiments, the aliphatic residues are selected from isoleucine, alanine, leucine, valine, and combinations thereof.

[0020] In some embodiments, the peptide includes 1 or 2 aliphatic residues. In some embodiments, the at least one GX or XG dyad is at least two GX or XG dyads. In some embodiments, the at least one aromatic amino acid is selected from tryptophan, phenylalanine, tyrosine, and histidine. In some embodiments, the at least one aromatic amino acid is at least two or at least three aromatic amino acids. In some embodiments, the peptide includes an elastin-like polypeptide domain (ELP: Pro-Gly-Val-Gly, SEQ ID NO: 13). In some embodiments, the peptide includes a sequence selected from SEQ ID Nos: 1, 14-15, 2-7, 16-17, and 8-12.In some embodiments, the peptide is at a concentration of about 2.5-20 mM.

[0021] In some embodiments, the aqueous buffer is selected from a 2-(N-morpholino)ethanesulfonic acid (MES) buffer, a citrate buffer, a phosphate buffer, HEPES (4-(2-hy droxy ethyl)- 1 -piperazineethanesulfonic acid), and a Tris buffer.

[0022] In some embodiments, the buffer concentration is about 5-50 mM.

[0023] In some embodiments, the pH of the composition is about 5-8.

[0024] In some embodiments, the azide-containing compound is 3-azido-7-hydroxycoumarin (AHC).

[0025] In some embodiments, the alkyne-containing compound is 4-ethynylanisole.

[0026] In some embodiments, the copper salt is selected from CuSCE, CuCh, copper nitrate, and copper acetate.

[0027] In some embodiments, the copper salt is at a concentration of about 100 pM - 50 mM. In some embodiments, the composition does not include a salt in addition to the copper salt. In some embodiments, the composition further includes a reducing agent. In some embodiments, the reducing agent is sodium ascorbate.

[0028] In some embodiments, the composition further includes a reaction product at least partially encapsulated within the condensate.

[0029] In some embodiments, the CuAAC reaction is for preparing an antibody-drug conjugate (ADC); one of the azide-containing compound and the alkyne-containing compound is linked to a monoclonal antibody (mAb); and another one of the azide-containing compound and the alkyne-containing compound is linked to a drug.

[0030] In some embodiments, the mAb is a monoclonal antibody suitable for treating cancer or for cosmetic treatment. In some embodiments, the mAb is selected from cetuximab, panitumumab, rituximab, obinutuzumab, ofatumumab, bevacizumab, infliximab, trastuzumab, pertuzumab, sacituzumab, zolbetuximab, enfortumab, tisotumab, mirvetuximab, inotuzumab, loncastuximab, brentuximab, gemtuzumab, polatuzumab, and belantamab.

[0031] In some embodiments, the drug is a drug suitable for treating cancer or for cosmetic treatment. In some embodiments, the drug is a cytotoxic drug or an immune modulator. In some embodiments, the cytotoxic drug is selected from an auristatin (such as monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), a maytansinoid, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, a camptothecin derivative, a-amanitin, a tubulin inhibitor (such as a tubulysin or an eribulin derivative), an irinotecan or a metabolite thereof (such as 7 -ethyl- 10-hydroxycamptothecin (SN-38)), and aBCL-XL inhibitor.

[0032] In some embodiments, the monoclonal antibody (mAb) and / or the drug are at least 90%encapsulated within the condensate.

[0033] In some embodiments, the composition further includes ADCs at least partially encapsulated within the condensate, wherein at least 70% of the ADCs have a drug-antibody ratio (DAR) which does not vary by more than 1 unit from an average DAR of the ADCs or from a target DAR.

[0034] In some embodiments, there is provided method for conducting a CuAAC reaction in a peptide-based condensate, the method including:

[0035] a) preparing an aqueous composition including a first CuAAC reagent and a second CuAAC reagent in peptide-based condensates in an aqueous buffer by:

[0036] i. combining the peptide, a copper salt, and the first CuAAC reagent, in the aqueous buffer to form the peptide-based condensate by liquid-liquid phase separation (LLPS), and adding the second CuAAC reagent following the LLPS to form the aqueous composition; or

[0037] ii. combining the peptide and the first CuAAC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second CuAAC reagent and the copper salt following the LLPS to form the aqueous composition, and b) incubating the aqueous composition until reaction products form,

[0038] wherein:

[0039] the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;

[0040] the G in the GX or XG dyad is glycine;

[0041] the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid; and

[0042] the first and the second CuAAC reagents together include both an azide-containing compound and an alkyne-containing compound and following LLPS become at least partially encapsulated within the condensate.

[0043] In some embodiments, the method further includes a step, following formation of the products, including centrifugation of the composition to separate the products present in the condensate from the copper ions, and decanting the copper-containing dilute phase.

[0044] In some embodiments, the CuAAC reaction is for preparing an antibody-drug conjugate (ADC); one of the azide-containing compound and the alkyne-containing compound is linked to a monoclonal antibody (mAb); and another one of the azide-containing compound and the alkyne-containing compound is linked to a drug.

[0045] In some embodiments, the method further includes a step, following formation of the ADCs, including filtering the composition to separate the ADCs from the peptide.In some embodiments, there is provided a method for preparing antibody-drug conjugates (ADC)s by a Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction in a peptide-based condensate, the method including:

[0046] a) preparing an aqueous composition including a first and a second ADC reagents in peptide- based condensates in an aqueous buffer by:

[0047] i. combining the peptide, a copper salt, and the first ADC reagent, in the aqueous buffer to form the peptide-based condensate by liquid-liquid phase separation (LLPS), and adding the second ADC reagent to form the aqueous composition; or ii. combining the peptide and the first ADC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second ADC reagent and the copper salt following the LLPS to form the aqueous composition, and b) incubating the aqueous composition until ADCs form,

[0048] wherein:

[0049] the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;

[0050] the G in the GX or XG dyad is glycine;

[0051] the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid;

[0052] the first and the second ADC reagents together include both an mAb and a drug and following LLPS become at least partially encapsulated within the condensate; and

[0053] one of the mAb and the drug is linked to an azide-containing compound and the other one of the mAb and the drug is linked to an alkyne-containing compound.

[0054] In addition to the exemplary embodiments described above, further embodiments will become apparent by reference to the figures and by study of the following detailed descriptions.

[0055] BRIEF DESCRIPTION OF DRAWINGS

[0056] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of necessary fee.

[0057] The invention will now be described in relation to certain examples and embodiments with reference to the following illustrative figures.

[0058] Figs. 1A-1C. Hydrophobicity of peptide condensates regulates chemical reactions. Fig. 1A.

[0059] Schematics of the suggested system: LLPS-promoting peptide building blocks with varying levelof hydrophobicity form biomolecular condensates for regulation of a Click chemistry (CuAAC) reaction. Fig. IB. Phase diagram heatmaps of WGI-0 (upper left panel), WGI-1 (upper right panel), and WGI-2 (lower panel) showing droplet formation by microscopy imaging as a function of peptide and CuSC concentration. Peptides were dissolved in 20 mM citrate buffer pH 5.4. Turbidity intensity was monitored at <=400 nm. The level of turbidity by Arbitrary Units (AU) is shown by shades of yellow-red. Fig. 1C. Microscopy analysis of the peptides as a function of peptide and CuSC concentration. Scale bar=10 pm.

[0060] Figs. 2A-2F. Deciphering the factors affecting reactant recruitment to condensates. Figs.

[0061] 2A-2B. Encapsulation efficiency (EE) of AHC in WGI-0 (Fig. 2A) or WGI-1 (Fig. 2B) condensates in citrate buffer, with peptides at concentrations of 5 mM, 10 mM, and 20 mM. Figs.

[0062] 2C-2D. The effect of replacing the citrate buffer with MES buffer for WGI-0 (Fig. 2C) or WGI-1 (Fig. 2D). Figs. 2E-2F. The effect on EE of salts (Fig. 2E) and azide group (Fig. 2F) in WGI-0 condensates. Values presented as box plots based on n=4-6.

[0063] Figs. 3A-3I. Reaction conversion kinetics in phase separated systems. Figs. 3A-3B.

[0064] Reaction conversion over time (Fig. 3A) and initial reaction rate (Fig. 3B ) in either citrate buffer (squares), double distilled water (DDW, circles), or in phase separated systems formed by 5 mM of WGI-0 (triangles), WGI-1 (diamonds), of WGI-2 (hexagons), in citrate buffer pH 5.4. All reactions contain 5% of t-BtOH (tert-butanol). Analyses were performed by HPLC, following quenching of the reaction at each time point. Values represent averages (Fig.3A) or box plot (Fig.

[0065] 3B) of either three, four, or 5 independent analyses for the reaction in buffer, each of the LLPS system, and DDW, respectively. Error bars in panels a and d represent S.D. Fig. 3C. Brightfield microscopy analysis of condensates over reaction time. Scale bars=25 pm. Figs.3D -3E. Reactions in the presence of WGI-0 (triangles), WGLl (diamonds), or only in citrate buffer (squares) at a concentration below Csat(2mM), where no condensates form. Values represent averages of three independent analyses, error bars represent S.D. * / ? value <0.05, ** / ? value <0.01. Figs. 3F-3G.

[0066] Reaction conversion overtime (Fig.3F) and initial reaction rate (Fig.3G) in DDW (circles), MES buffer alone at pH 5.7 (squares), or phase separated systems formed by 20 mM of WGLO (triangles) or WGLl (diamonds) in MES buffer pH 5.7. All reactions contain 5% of t-BtOH. Analyses were performed by HPLC, following quenching of the reaction at each time point. Values represent averages of three independent analyses, error bars represent S.D. Figs. 3H-3I. CLSM analysis of product fluorescence in WGLO and WGLl LLPS systems in either citrate buffer (pH=5.4, Fig. 3H) or MES buffer (pH=5.7, Fig. 31). Condensates were formed in citrate or MES buffer by 5 mM of each peptide. CLSM images collected Xex=405 nm. Scale bars= 2 pm. The relative fluorescence intensity (fraction) of products in the dense (droplets) vs dilute phaseobtained from CLSM analysis is presented on the right-most panel (upper in the page): red: droplets; black: dilute phase.

[0067] Figs. 4A-4I. Condensate dynamics is directly affected by the number of He in the peptide sequence. WGI-0, WGI-1, and WGI-2 condensates were formed by 10 mM of each peptide and 10 mM CuSO4. Fig. 4A. Encapsulation efficiency (EE) of rhodamine B in WGI-0, WGI-1, and WGI-2 condensates and in the WGI-2 condensate without CuSO4. Fig. 4B. ti / 2 values of WGI-0, WGI-1, and WGI-2 without Cu condensates in citrate buffer. Figs.4C-4F. Recovery plots of WGI-0 (Fig. 4C), WGI-1 (Fig. 4D), WGI-2 (Fig. 4E), and WGI-2 without Cu (Fig. 4F) condensates.

[0068] Figs. 4G-4H. Recovery plots (Fig. 4G) and the respective Zl / 2 values (Fig. 4H) of WGI-0 and WGI-1 (20 mM) in MES buffer, pH 5.7. Recovery plots and ti / 2 values represent average of n=5 condensates for WGI-0, n=9 for WGI-1, n=8 for WGI-2. Fig. 41. Confocal laser scanning microscopy (CLSM) images of condensates before, immediately after, and 50 sec after photobleaching. FRAP analysis was performed using rhodamine B (10 / M) and fluorescein (10 / M) in citrate and MES buffer, respectively. Scale bars=2 pm.

[0069] Figs. 5A-5H Cu2+-ion localization and exclusion from peptide condensates. Condensates were formed by 5 mM peptide and 10 mM CuSO4 in citrate buffer, pH 5.4. Scanning transmission electron microscopy (STEM) high-angle annular dark-field (HAADF) imaging combined with energy-dispersive spectroscopy (EDS) analysis of WGI-0 (Figs. 5A-5B), WGI-1 (Figs. 5C-5D), and WGI-2 (Figs. 5E-5F) condensates. Figs. 5A, 5C, 5E: micrographs showing dark-field (left) and EDS (right) elemental maps of copper (Cu). Figs. 5B, 5D, 5F: line scan mapping showing the net intensity of Cu. Scale bar = 500 nm. Figs. 5G-5H. Quantification of Cu2+ions in supernatants (dilute phase) following droplet centrifugation using ICP-MS (inductively coupled plasma mass spectrometry) (Fig. 5G), or absorption spectroscopy at X=750 nm (Fig. 5H).

[0070] Fig- 6 Schematic illustration of the workflow including ADCs conjugation in condensates and downstream processing.

[0071] Figs.7A-7D. Encapsulation efficiency (EE) of the model antibodies rituximab, bevacizumab (Avastin®), and infliximab in peptide condensates show high (>95%) recruitment of the three mAb. Fig. 7A. EE analysis based on absorbance spectroscopy using Alexafluor594-labeled antibodies after centrifugation of mAb-loaded condensates. Figs. 7B-7D. CLSM analysis of rituximab (Fig. 7B), bevacizumab (Fig. 7C), and infliximab (Fig. 7D) recruitment in the peptide condensates. Each mAb was labeled with Alexafluor594, excitation laser is 560 nm.DETAILED DESCRIPTION OF THE INVENTION

[0072] In the following description, various aspects of the disclosure will be described. For the purpose of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the different aspects of the disclosure. However, it will also be apparent to one skilled in the art that the disclosure may be practiced without specific details being presented herein. Furthermore, well-known features may be omitted or simplified in order not to obscure the disclosure.

[0073] In the present invention, peptide-based condensates have been developed for carrying out reactions involving hydrophobic reagents in aqueous environments and for finding the best conditions for these reactions. The advantage of peptide-based condensates is that the condensates (dense phase formed by the peptide) encapsulate and concentrate the hydrophobic reagents, causing the reaction to be faster and more efficient.

[0074] The inventors chose to focus on the Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC, a type of a Click chemistry reaction), which is a widely used transformation in drug discovery, proteomics, and materials science. This reaction, between two hydrophobic azide / alkyne-containing reactants, forms a traceable aromatic triazole product under mild conditions in aqueous environments, providing an ideal platform for studying the interplay of condensate microenvironment and reaction kinetics.

[0075] To create biomolecular condensates providing a hydrophobic microenvironment for compartmentalization of the CuAAC reaction and testing the effect on reaction rate and conversion, varying number of aliphatic residues (isoleucine, (He), valine (Vai)) were incorporated into previously designed liquid-liquid phase separation (LLPS)-promoting peptides. Specifically, 1 (WGI-1) or 2 (WGI-2) aliphatic amino acids (e.g., He) were added to the original peptide (WGI-0) which already included 1 aliphatic residue (Vai, as part of an elastin-like polypeptide domain (ELP)). Accordingly, WGI-0 has 1 aliphatic residue, WGI-1 has 2 aliphatic residues, and WGI-2 has 3 aliphatic residues.

[0076] Condensates formed by a moderately hydrophobic peptides (containing 1 or 2 hydrophobic residues per 14 amino acids) achieved an optimal balance between reactant recruitment and catalytic efficiency, while excessive hydrophobicity of the peptide resulted in solid-like condensates that impeded catalysis.

[0077] As described in Example 2 (Fig.2), 3 -azido-7-hydroxy coumarin (AHC, a CuAAC reagent) was successfully encapsulated to varying degrees by the condensates at different concentrations and in different buffers, with the best result of over 90% encapsulation obtained with 20 mM of WGI-1 in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (Fig. 2D).Example 3 ( Fig.3) describes the effect of various parameters on reaction rate, as measured by formation of the triazole product of the CuAAC reaction. While products were formed in all condensates, a very low peptide concentration (2 mM, below saturation) where condensates were not formed, resulted in very low conversion rates, similar to buffer alone, demonstrating the advantage of the condensate system (Figs. 3D-3E). Also in this analysis, the best results were obtained for a high peptide concentration of 20 mM, in MES buffer (Fig. 3F-3G).

[0078] The inventors further demonstrate that when the reaction products are encapsulated in the condensate, a simple centrifugation may be carried out in order to separate the products from the potentially harmful copper ions (Figs. 5G-5H).

[0079] A more specific example for a CuAAC reaction, also suitable for use with the peptide-based condensate system of the invention, is preparation of antibody-drug conjugates (ADC)s.

[0080] Antibody-drug conjugates (ADCs) are a promising class of targeted therapeutics, combining the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of smallmolecule drugs. Several ADCs, including anticancer therapies like Kadcyla® (trastuzumab emtansine), Adcetris® (brentuximab vedotin) and Polivy® (polatuzumab vedotin) already demonstrated clear clinical benefits. However, the development, scalability, and industrial adoption of ADCs are still constrained by fundamental limitations which limit the number of ADC candidates that successfully progress through clinical development.

[0081] The two main conjugation methods of ADCs are currently used are N-hydroxysuccinimide (NHS)-ester coupling (lysine-based conjugation) and maleimide-thiol coupling (cysteine-based conjugation). The first results in a wide distribution of drug-antibody ratio (DAR) due, inter alia, to the large number of accessible lysines, leading to batch-to-batch variability and heterogenous mixtures; while the second requires chemical reduction of disulfides, which may lead, inter alia, to antibody misfolding and loss of binding capability.

[0082] CuAAC click chemistry reaction offers significant advantages for ADC manufacturing, allowing high site specificity and efficient coupling under mild conditions. CuAAC reaction offers precise control of the site and number of conjugated drug molecules, yielding homogeneous ADCs with predictable therapeutic profiles. These advantages make CuAAC reaction an attractive platform for developing next-generation ADCs with improved efficacy and manufacturing reproducibility.

[0083] However, one of the most significant challenges for CuAAC reactions is the cytotoxicity of the copper catalyst, which can lead to intracellular oxidative stress. Copper-free CuAAC reactions can overcome this challenge but require engineering of antibodies with cyclooctyne handles, which are bulkier compared to regular alkyne derivatives and might hinder binding. In addition,engineering mAb with these handles increase the ADC production cost and slows the kinetics of the reaction.

[0084] The peptide-based condensate system of the invention designed for CuAAC reactions, in addition to its ability to concentrate the reaction and provide a selective environment, can also solve the copper toxicity problem as well. Since the ADCs are encapsulated in the condensate and the copper ions are in the dilute phase, a simple centrifugation step causes the condensates to coalesce into a distinct dense phase that excludes water, co-solutes, and copper ions, thereby allowing a one-step purification of the ADCs. This effectively results in separation of the dense phase enriched in conjugated ADCs from the surrounding dilute phase containing copper ions, thereby significantly simplifying downstream purification.

[0085] Table 1: A comparison of ADC production methods

[0086] Aspect NHS-Ester Maleimide- CuAAC Cu-Free CuAAC in Coupling Thiol Coupling AAC peptide condensates Site Specificity Low Moderate High High High Reaction Low-moderate Moderate High Low High Efficiency

[0087] Product Low Moderate High High High Homogeneity

[0088] (DAR)

[0089] Stability of Linkage Poor Moderate Excellent Excellent Excellent Copper Catalyst Not relevant Not relevant Yes No No Toxicity

[0090] Downstream Complex Moderate Complex Moderate Simple Purification

[0091] Scalability High High Moderate Moderate Modular and scalable Limitations Heterogeneous, Misfolding, Cu Slow Requires aggregation retro-Michael toxicity reaction peptide

[0092]

[0093] risk reaction design DAR: drug-antibody ratio

[0094] Fig. 6 provides an overview of ADC preparation by the condensates of the invention. As described, following ADC formation the copper ions may be removed by centrifugation, as explained above. Furthermore, the large ADC molecules may be separated from the peptide by filtration, thereby allowing reuse of the peptide by adding fresh CuAAC reagents. At this point, a proof of concept for encapsulation of antibodies by the peptide-based condensates is provided in Fig. 7.Compositions including a peptide-based condensate

[0095] Accordingly, in some embodiments, there is provided an aqueous composition including a peptide-based condensate in an aqueous buffer, the condensate including:

[0096] a peptide including at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues; and

[0097] reagents for a CuAAC reaction including an azide-containing compound and an alkyne- containing compound, and a copper salt,

[0098] wherein the G in the GX or XG dyad is glycine (Gly); and the X in the GX or XG dyad is selected from arginine (Arg, R), lysine (Lys, K), aspartic acid (Asp, D), and Glutamic acid (Glu, E).

[0099] It is understood that the CuAAC reagents are at least partially encapsulated within the condensate.

[0100] The peptide-based condensate of the invention is formed by LLPS, resulting in a dense phase (the condensate), which includes most of the peptide molecules and the CuAAC reagents, and a dilute phase which includes a low concentration of peptide molecules and the CuAAC reagents.

[0101] The term “encapsulated”, as used herein (with reference to reagents or product), means -present in the dense phase, i.e., in the condensate.

[0102] In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the total amount of the reagents is encapsulated within the condensate. In some embodiments, at least about 50% of the total amount of the reagents is encapsulated within the condensate. In some embodiments, at least about 70% of the total amount of the reagents is encapsulated within the condensate. In some embodiments, at least about 90% of the total amount of the reagents is encapsulated within the condensate.

[0103] Low amount of an organic solvent

[0104] In some embodiments, the composition includes less than 10% of an organic solvent. In some embodiments, the composition includes less than 5% of an organic solvent. In some embodiments, the composition includes 2% or less of an organic solvent.

[0105] In some embodiments, the organic solvent is selected from butanol, ethanol, methanol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), acetonitrile, 1,4-di oxane, tetrahydrofuran (THF), and isopropanol.

[0106] In some embodiments, the organic solvent is butanol. In some embodiments, the organic solvent is tert-butanol.

[0107] In some embodiments, the composition does not include an organic solvent.The peptide

[0108] In some embodiments, the peptide has a length of about 10-20 amino acids. In some embodiments, the peptide has a length of about 10-15 amino acids. In some embodiments, the peptide has a length of about 14 amino acids.

[0109] In some embodiments, the aliphatic residues are selected from isoleucine, alanine, leucine, valine, and combinations thereof.

[0110] In some embodiments, the peptide includes 1 or 2 aliphatic residues. In some embodiments, the peptide includes 1 aliphatic residue. In some embodiments, the peptide includes 2 aliphatic residues.

[0111] In some embodiments, the aliphatic residues constitute about 20% or less of the total number of amino acids in the peptide. In some embodiments, the aliphatic residues constitute about 15% or less of the total number of amino acids in the peptide. In some embodiments, the aliphatic residues constitute about 5%-l 5% of the total number of amino acids in the peptide.

[0112] The term “at least one GX or XG dyad” encompasses a single GX or XG dyad as well as multiple dyads including one or more GX dyads and / or one or more XG dyads.

[0113] In some embodiments, the X in the GX or XG dyad is Arg or Lys. In some embodiments, the X in the GX or XG dyad is Asp or Gly. In some embodiments, the X in the GX or XG dyad is Arg. In some embodiments, the X in the GX or XG dyad is Lys. In some embodiments, the X in the GX or XG dyad is Asp. In some embodiments, the X in the GX or XG dyad is Glu.

[0114] In some embodiments, the at least one GX or XG dyad is at least two GX or XG dyads. In some embodiments, the at least one GX or XG dyad is at least three GX or XG dyads. In some embodiments, the GX or XG dyads are not separated by other amino acids (i.e., that are not Arg, Lys, Asp, or Glu). In some embodiments, the peptide includes at least two GX or XG dyads that are separated by at least one amino acid that is not Arg, Lys, Asp, or Glu.

[0115] In some embodiments, when the at least one GX or XG dyad is more than one GX or XG dyad (e.g., at least two or at least three GX or XG dyads), the X is the same amino acid in all dyads. In some embodiments, when the at least one GX or XG dyad is more than one GX or XG dyad, X is not the same amino acid in all dyads (but could be the same in some of the dyads).

[0116] In some embodiments, the at least one GX or XG dyad includes only GX dyads. In some embodiments, the at least one GX or XG dyad includes only XG dyads. In some embodiments, the at least one GX or XG dyad is more than one dyad, including both GX and XG dyads.

[0117] In some embodiments, the at least one aromatic amino acid is selected from tryptophan (Trp, W), phenylalanine (Phe, F), tyrosine (Tyr, Y), and histidine (His, H). In some embodiments, the at least one aromatic amino include at least one Trp. In some embodiments, the at least onearomatic amino includes at least one Tyr. In some embodiments, the at least one aromatic amino includes at least two Trp residues. In some embodiments, the at least one aromatic amino includes at least two Trp residues and at least one Tyr.

[0118] In some embodiments, the at least one aromatic amino acid is at least two aromatic amino acids. In some embodiments, the at least one aromatic amino acid is at least three aromatic amino acids.

[0119] In some embodiments, the peptide further includes additional glycines and / or polar residues that enhance hydration and mobility, to retain diffusion within the dense phase.

[0120] In some embodiments, the peptide includes an ELP (Pro-Gly-Val-Gly, PGVG, SEQ ID NO: 13) domain.

[0121] In some embodiments, the peptide includes about 25%-45% GX or XG dyads, a total of about 7%- 15% aliphatic residues, a total of about 21% aromatic amino acids, a total of about 40%-50% glycine residues, and an ELP domain sequence.

[0122] In some embodiments, the peptide has a length of about 14-15 amino acids, and includes 2-3 GX or XG dyads, a total of 1-2 aliphatic residues, a total of three aromatic amino acids, a total of six glycine residues, and an ELP domain sequence.

[0123] In some embodiments, the peptide includes a sequence selected from: WGRGRGRGWPGVGY (WGI-0, SEQ ID NO: 1); WGIGRGRGWPGVGY (WGI-1, SEQ ID NO: 14), WGIGRIRGWPGVGY (WGI-2, SEQ ID NO: 15), WGRGRGRGWPGVGF (SEQ ID NO: 2), WGRGRGRGWY (SEQ ID NO: 3), WGRGRGWPGVGY (SEQ ID NO: 4), WGRGRGRGWQGVGY (SEQ ID NO: 5); WGRGRGRWY(SEQ ID NO: 6);

[0124] WGEGEGEGWPGVGY (corresponding to WGLO with Glu instead of Arg, SEQ ID NO: 7), WGIGEGEGWPGVGY (corresponding to WGI-1 with Glu instead of Arg, SEQ ID NO: 16), WGIGEIEGWPGVGY (corresponding to WGI-2, SEQ ID NO: 17), WGEGEGEGWPGVGF (SEQ ID NO: 8), WGEGEGEGWY (SEQ ID NO: 9), WGEGEGWPGVGY (SEQ ID NO: 10), WGEGEGEGWQGVGY (SEQ ID NO: 11); and WGEGEGEWY (SEQ ID NO: 12).

[0125] In some embodiments, the peptide is selected from SEQ ID Nos: 1, 14-15, and 2-6.

[0126] In some embodiments, the peptide is selected from SEQ ID Nos: 1, 14-15, 7, and 16-17.

[0127] In some embodiments, the peptide is selected from SEQ ID Nos: 1, 14, 7, and 16.

[0128] In some embodiments, the peptide is selected from WGLO (SEQ ID NO: 1) and WGI-1 (SEQ ID NO: 14). In some embodiments, the peptide is WGI-O (SEQ ID NO: 1). In some embodiments, the peptide is WGI-1 (SEQ ID NO: 14).

[0129] In some embodiments, the peptide is at a concentration of at least about 1 mM, 2 mM, 5 mM, or 10 mM. In some embodiments, the peptide is at a concentration of above 2 mM. In someembodiments, the peptide is at a concentration of about 2.5-25 mM. In some embodiments, the peptide is at a concentration of about 2.5-20 mM. In some embodiments, the peptide is at a concentration of about 5-20 mM. In some embodiments, the peptide is at a concentration of about 10-20 mM. In some embodiments, the peptide is at a concentration of about 2.5 mM. In some embodiments, the peptide is at a concentration of about 5 mM. In some embodiments, the peptide is at a concentration of about 10 mM. In some embodiments, the peptide is at a concentration of about 20 mM.

[0130] In some embodiments, the peptide includes a combination of two or more peptides, each including: at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues.

[0131] In some embodiments, the peptide is a combination of a positively-charged peptide and a negatively-charged peptide. In some embodiments, the peptide includes a combination of a first and a second peptide, wherein in all GX or XG dyads in the first peptide X is a basic (positively-charged) amino acid (such as Arg or Lys) and in all GX or XG dyads in the second peptide X is an acidic (negatively-charged) amino acid (such as Asp or Glu).

[0132] In some embodiments, the peptide includes a combination of a first peptide and a second peptide which are identical except for that all of the positively-charged amino acids (arginines or lysines) in the first peptide are replaced with negatively charged amino acids (glutamic or aspartic acid) in the second peptide. For example, in some embodiments, the peptide includes a combination of SEQ ID NO: 1 and SEQ ID NO: 7 In some embodiments, the peptide includes a combination of SEQ ID NO: 14 and SEQ ID NO: 16.

[0133] The aqueous buffer

[0134] In some embodiments, the aqueous buffer is selected from a 2-(N-morpholino)ethanesulfonic acid (MES) buffer, a citrate buffer, a phosphate buffer, HEPES (4-(2-hy droxy ethyl)- 1 -piperazineethanesulfonic acid), and a Tris buffer.

[0135] In some embodiments, the aqueous buffer is an MES buffer or a citrate buffer. In some embodiments, the aqueous buffer is a citrate buffer. In some embodiments, the aqueous buffer is an MES buffer.

[0136] In some embodiments, the buffer concentration is about 5-50 mM. In some embodiments, the buffer concentration is about 5-40 mM. In some embodiments, the buffer concentration is about 5-30 mM. In some embodiments, the buffer concentration is about 5-20 mM. In some embodiments, the buffer concentration is about 5-10 mM. In some embodiments, the buffer concentration is about 5 mM. In some embodiments, the buffer concentration is about 10 mM. In some embodiments, the buffer concentration is about 20 mM. In some embodiments, the bufferconcentration is about 30 mM. In some embodiments, the buffer concentration is about 40 mM. In some embodiments, the buffer concentration is about 50 mM.

[0137] In some embodiments, the pH of the composition is about 5-8. In some embodiments, the pH of the composition is about 5-6. In some embodiments, the pH of the composition is about 5.4-5.7. In some embodiments, the pH of the composition is less than 6. In some embodiments, the pH of the composition is about 5.4. In some embodiments, the pH of the composition is about 5.7.

[0138] In some embodiments, the peptide includes 2 aliphatic amino acids and the pH of the composition is acidic. In some embodiments, the peptide includes 2 aliphatic amino acids and the pH of the composition is about 5-6. In some embodiments, the peptide includes 2 aliphatic amino acids and the pH of the composition is about 5.4. In some embodiments, the peptide includes 2 aliphatic amino acids and the pH of the composition is about 5.7. In some embodiments, the peptide includes 2 aliphatic amino acids and the buffer is a citrate buffer. In some embodiments, the peptide includes 2 aliphatic amino acids and the buffer is an MES buffer.

[0139] In some embodiments, the peptide includes 1 aliphatic amino acid and the pH of the composition is acidic. In some embodiments, the peptide includes 1 aliphatic amino acid and the pH of the composition is about 5-6. In some embodiments, the peptide includes 1 aliphatic amino acid and the pH of the composition is about 5.4. In some embodiments, the peptide includes 1 aliphatic amino acid and the pH of the composition is about 5.7. In some embodiments, the peptide includes 1 aliphatic amino acid and the buffer is a citrate buffer. In some embodiments, the peptide includes 1 aliphatic amino acid and the buffer is an MES buffer.

[0140] CuAAC reagents and products

[0141] The term “azide-containing compound”, as used herein, relates to molecules which include an azide (N3) functional group.

[0142] Nonlimiting examples of suitable azide-containing compounds include 3-azido-7-hydroxycoumarin (AHC), azido-fluorescein, azi do-rhodamine, azido-BODZPY™, Alexa fluor azide-containing dyes (e.g., Alexa Fluor 488 azide), Cy5 azide, azidoacetyl group, azidopropionyl group, azido-PEG (PEGn-Ns), NHS-azide (e.g., NHS-azidoacetate), iodoacetamide-Ns, maleimide-PEG-Ns, hydrazide-Ns, aminooxy-Ns, azido-sugar derivatives (GalNAz, ManNAz, SiaNAz), p-azidophenylalanine (pAzF), azidohomoalanine (AHA), s-azidoacetyl-lysine, cadaverine-Ns, and Gly-Gly-Gly-Ns.

[0143] In some embodiments, the azide-containing compound is AHC. In some embodiments, the azide-containing compound is UDP-GalNAz. In some embodiments, the azide-containing compound is selected from AHC, azido-fluorescein, azido-rhodamine, azido-BODIPY™, Alexafluor azide-containing dyes (e.g., Alexa Fluor 488 azide), and Cy5 azide.

[0144] The term “alkyne-containing compound”, as used herein, relates to molecules which include an alkyne group.

[0145] In some embodiments, the alkyne-containing compound includes a terminal alkyne. Nonlimiting examples of suitable alkyne-containing compounds include 4-Ethynylanisole, propargyl fluorescein, alkyne-BODIPY™, TAMRA alkyne, alkyne-Cy5, propargyl group (such as propargyl ether, propargyl amide, propargyl ester, and propargyl carbamate), pentynyl group, hexynyl group, alkynyl-PEG (e.g., PEG4-alkyne), alkynyl sulfonamide, alkynyl carbamate, terminal alkyne-fun ctionalized aromatic ring (e.g., phenylacetylene), terminal alkynyl alcohol.

[0146] In some embodiments, the copper salt is selected from CuSCU, CuCh, copper nitrate, and copper acetate. In some embodiments, the copper salt is CuSCU.

[0147] In the present invention, the copper salt may be used both as a reaction initiator and for the phase separation, which obviates the need for an additional salt for the phase separation. Therefore, in some embodiments, the aqueous composition does not include a salt in addition to the copper salt. In other words, the copper salt may be the sole salt included in the composition.

[0148] However, the system of the invention may be used with an additional salt for the phase separation. Accordingly, in some embodiments, the aqueous composition further includes a phase separation salt. In some embodiments, the phase separation salt is selected from sodium salt, potassium salt, magnesium salt, calcium salt, zinc salt, manganese salt, iron salt, cobalt salt, and nickel salt. In some embodiments, the sodium salt is NaCl or Na2SO4.

[0149] In some embodiments, the copper salt is at a concentration of about 100 pM - 50 mM. In some embodiments, the copper salt is at a concentration of about 1-50 mM. In some embodiments, the copper salt is at a concentration of about 5-50 mM. In some embodiments, the copper salt is at a concentration of about 5-20 mM. In some embodiments, the copper salt is at a concentration of about 20 mM. In some embodiments, the copper salt is at a concentration of about 10 mM. In some embodiments, the copper salt is at a concentration of about 5 mM.

[0150] In some embodiments, the aqueous composition further includes a reducing agent.

[0151] In some embodiments, the reducing agent is sodium ascorbate.

[0152] In some embodiments, the CuAAC reaction yields a reaction product that is at least partially encapsulated within the condensate. In some embodiments, the CuAAC reaction yields a reaction product that is mostly excluded from the condensate.

[0153] In some embodiments, the reaction product is a triazole. In some embodiments, the triazole is 1, 2, 3 triazole. In some embodiments, the triazole is 7-hydroxy-3-(4-(4-methoxyphenyl)-lH-1 ,2,3 -tri azol- 1 -yl)-2H-chromen-2-one.In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the total amount of the reaction products is encapsulated within the condensate. In some embodiments, at least about 50% of the total amount of the reaction products is encapsulated within the condensate. In some embodiments, at least about 70% of the total amount of the reaction products is encapsulated within the condensate. In some embodiments, at least about 90% of the total amount of the reaction products is encapsulated within the condensate.

[0154] Reaction parameters

[0155] In some embodiments, the encapsulation efficiency of the CuAAC reagents in the condensate is at least about 30%. In some embodiments, the encapsulation efficiency of the CuAAC reagents in the condensate is at least about 40%. In some embodiments, the encapsulation efficiency of the CuAAC reagents in the condensate is at least about 50%. In some embodiments, the encapsulation efficiency of the reagents in the condensate is at least about 60%. In some embodiments, the encapsulation efficiency of the reagents in the condensate is at least about 70%. In some embodiments, the encapsulation efficiency of the reagents in the condensate is at least about 80%. In some embodiments, the encapsulation efficiency of the reagents in the condensate is at least about 90%.

[0156] In some embodiments, the reaction rate is at least about 10 pM product generated per minute. In some embodiments, the reaction rate is at least about 15 pM product generated per minute. In some embodiments, the reaction rate is at least about 20 pM product generated per minute. In some embodiments, the reaction rate is at least about 25 pM product generated per minute.

[0157] Preparing ADCs — a private case of CuAAC reactions

[0158] As explained above, a private case of CuAAC reactions includes reactions for preparing ADCs. In these reactions, a monoclonal antibody (mAb) is conjugated to a desired drug by the CuAAC reaction. For that purpose, the CuAAC reagents are more specifically ADC reagents, including the mAb and the drug modified by conjugating one to the azide-containing compound and the other to the alkyne-containing compound.

[0159] Accordingly, in some embodiments, the CuAAC reaction is for preparing ADCs from an mAb and a drug. In some embodiments, the ADC reagents are reagents for preparing ADCs by a CuAAC reaction including an mAb and a drug, as further detailed below. In some embodiments, one of the mAb and the drug is conjugated to the azide-containing compound and the other one of the mAb and the drug is conjugated to the alkyne-containing compound

[0160] In some embodiments, there is provided an aqueous composition including a peptide-basedcondensate in an aqueous buffer, the condensate including:

[0161] a peptide including at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues; and

[0162] reagents for preparing ADCs by a CuAAC reaction including a monoclonal antibody (mAb) and a drug, and a copper salt,

[0163] wherein the G in the GX or XG dyad is Gly;

[0164] the X in the GX or XG dyad is selected from Arg, Lys, Asp, and Glu; and

[0165] one of the mAb and the drug is conjugated to an azide-containing compound and the other one of the mAb and the drug is conjugated to an alkyne-containing compound.

[0166] It is understood that the reagents are at least partially encapsulated within the condensate. In some embodiments, the composition further includes ADCs at least partially encapsulated within the condensate.

[0167] In some embodiments, there is provided an aqueous composition including a peptide-based condensate in an aqueous buffer, the condensate including:

[0168] a peptide including at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues; and

[0169] ADCs prepared by a CuAAC reaction from an mAb and a drug,

[0170] wherein:

[0171] the G in the GX or XG dyad is Gly;

[0172] the X in the GX or XG dyad is selected from Arg, Lys, Asp, and Glu; and

[0173] one of the mAb and the drug is conjugated to an azide-containing compound and the other one of the mAb and the drug is conjugated to an alkyne-containing compound.

[0174] It is understood that the ADCs are at least partially encapsulated within the condensate. Definitions and embodiments mentioned above and which may be relevant to the embodiments in this section also apply here, and vice versa. Some particularly relevant embodiments may be pointed out or explicitly repeated. For terms used herein, unless stated otherwise, their definition and embodiments are intended to be the same as above (mutatis mutandis).

[0175] In some embodiments, the azide-containing compound is linked to the mAb and the alkyne-containing compound is linked to the drug. In some embodiments, the alkyne-containing compound is linked to the mAb and the azide-containing compound is linked to the drug.

[0176] In some embodiments, the mAb is a monoclonal antibody suitable for treating cancer or for cosmetic treatment. In some embodiments, the mAb is selected from belantamab, bevacizumab, brentuximab, cetuximab, enfortumab, gemtuzumab, infliximab, inotuzumab, loncastuximab,mirvetuximab, obinutuzumab, ofatumumab, panitumumab, pertuzumab, polatuzumab, rituximab, sacituzumab, tisotumab, trastuzumab, and zolbetuximab.

[0177] In some embodiments, the mAb is selected cetuximab, rituximab, bevacizumab, and infliximab.

[0178] In some embodiments, the drug is a drug suitable for treating cancer or for cosmetic treatment.

[0179] In some embodiments, the drug is a cytotoxic drug or an immune modulator.

[0180] In some embodiments, the cytotoxic drug is selected from an auristatin (such as monomethyl auristatin E (MMAE, vedotin) or monomethyl auristatin F (MMAF)), a maytansinoid (such as DM1 (emtansine)), a calicheamicin (such as ozogamicin ), a duocarmycin, a pyrrolobenzodiazepine, a camptothecin derivative, a-amanitin, a tubulin inhibitor (such as a tubulysin or an eribulin derivative), an irinotecan or a metabolite thereof (such as 7 -ethyl- 10-hydroxycamptothecin (SN-38)), and aBCL-XL inhibitor.

[0181] In some embodiments, the ADCs are selected from trastuzumab emtansine, brentuximab vedotin, polatuzumab vedotin, Gemtuzumab ozogamicin, and inotuzumab ozogamicin.

[0182] In some embodiments, the at least 50%, 60%, 70%, 80%, 90%, or 95% of the reactants are encapsulated within the condensate.

[0183] In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or 95% of the ADCs are encapsulated within the condensate.

[0184] In some embodiments, the azide-containing compound is selected from an azidoacetyl group, an azidopropionyl group, an azido-PEG (PEGn-Ns), an NHS-azide (e.g., NHS-azidoacetate), an iodoacetamide-Ns, a maleimide-PEG-Ns, a hydrazide-Ns, an aminooxy-Ns, an azido-sugar derivative (GalNAz, ManNAz, SiaNAz), a p-azidophenylalanine (pAzF), an azidohomoalanine (AHA), an s-azidoacetyl-lysine, a cadaverine-Ns, and a Gly-Gly-Gly-Ns.

[0185] The azide-containing compound may be attached at any position on the mAb or the drug. Nonlimiting examples to amino acid side chains on the antibody which are suitable for azide attachment include side chains of lysine, cysteine, asparagine (via Fc N-glycan), tyrosine, methionine, and N-terminal residues.

[0186] In some embodiments, the azide-containing compound is not attached to lysine or to cysteine. In some embodiments, the azide is attached to asparagine.

[0187] In some embodiments, the alkyne-containing compound includes a terminal alkyne. Nonlimiting examples of suitable alkene-containing compounds include propargyl groups (such as propargyl ether, propargyl amide, propargyl ester, and propargyl carbamate), pentynyl group, hexynyl group, alkynyl-PEG (e.g., PEGt-alkyne), alkynyl sulfonamide, alkynyl carbamate,terminal alkyne-fun ctionalized aromatic ring (e.g., phenylacetylene), terminal alkynyl alcohol. In some embodiments, the ADCs include the mAh conjugated to the drug through a triazole ring.

[0188] A drug-antibody ratio (DAR) is important for ADCs, because it influences efficacy and safety. If the DAR is too low, the therapeutic may not deliver enough cytotoxic payload to effectively kill the target cells. If it is too high, the antibody can become unstable, aggregate more readily, or clear rapidly from circulation. A well-controlled and homogeneous DAR ensures reproducible pharmacokinetics, predictable pharmacodynamics, and a reliable therapeutic index across patient populations.

[0189] In some embodiments, a majority of the ADCs have a DAR which does not differ by more than 1 unit from an average DAR of the ADCs or from a target DAR.

[0190] In some embodiments, a minority of the ADCs have a DAR which is 0-1 or which differs from an average DAR of the ADCs or from a target DAR by at least 2 units.

[0191] In some embodiments, “a majority” is at least 60%. In some embodiments, “ a majority” is at least 70%. In some embodiments, “a majority” is at least 80%.

[0192] In some embodiments, “a minority” is not more than 30%. In some embodiments, “a minority” is not more than 20%. In some embodiments, “a minority” is not more than 10%.

[0193] In some embodiments, the target DAR is about 2-8. In some embodiments, the target DAR is about 2-5. In some embodiments, the target DAR is about 2-4.

[0194] Methods for conducting a CuAAC reaction in the condensates of the invention

[0195] In some embodiments, there is provided a method for conducting a CuAAC reaction in a peptide-based condensate, the method including:

[0196] a) preparing an aqueous composition including a first and a second CuAAC reagents in peptide-based condensates in an aqueous buffer by:

[0197] i. combining the peptide, a copper salt, and the first CuAAC reagent, in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second CuAAC reagent following the LLPS to form the aqueous composition; or

[0198] ii. combining the peptide and the first CuAAC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second CuAAC reagent and a copper salt following the LLPS to form the aqueous composition, and b) incubating the aqueous composition until reaction products form,

[0199] wherein:the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;

[0200] the G in the GX or XG dyad is glycine;

[0201] the X in the GX or XG dyad is selected from Arg, Lys, Asp, and Glu; and

[0202] the first and the second CuAAC reagents together include both an azide-containing compound and an alkyne-containing compound and following LLPS become at least partially encapsulated within the condensate.

[0203] In some embodiments, the first CuAAC reagent is an azide-containing compound and the second CuAAC reagent is an alkyne-containing compound. In some embodiments, the second CuAAC reagent is an azide-containing compound and the first CuAAC reagent is an alkyne-containing compound.

[0204] Definitions and embodiments mentioned above and which may be relevant to the embodiments in this section also apply here, and vice versa. Some particularly relevant embodiments may be pointed out or explicitly repeated. For terms used herein, unless stated otherwise, their definition and embodiments are intended to be the same as above (mutatis mutandis).

[0205] It is appreciated that the terms “combining” and “adding” with respect to ingredients are not intended to imply that the ingredients are added at the same time, and do not specify the order in which they are added. For example, combining the peptide, a copper salt, and the first CuAAC reagent in an aqueous buffer in Item a(i) or combining the peptide and the first CuAAC reagent in an aqueous buffer in Item a(ii), encompasses adding the peptide to an aqueous buffer containing the first reagent, or adding the first reagent to an aqueous buffer containing the peptide, and the copper salt may be added to an aqueous buffer containing the first reagent or to an aqueous buffer containing the peptide, or to an aqueous buffer containing both. Similarly, adding the second reagent and the copper salt in Item a(ii), encompasses adding them together or separately at any order.

[0206] In some embodiments, the method further includes adding a reducing agent to the composition in step (a). In some embodiments, the reducing agent is sodium ascorbate.

[0207] In some embodiments, the copper salt is selected from CuSCU, CuCh, copper nitrate, and copper acetate. In some embodiments, the copper salt is CuSCU.

[0208] In some embodiments, no additional salt is added.

[0209] In some embodiments, Item a(ii) further includes combining with the peptide and first reagent a phase separation salt that is not a copper salt to facilitate LLPS. In some embodiments, the phase separation salt is selected from sodium salt, potassium salt, magnesium salt, calciumsalt, zinc salt, manganese salt, iron salt, cobalt salt, and nickel salt. In some embodiments, the sodium salt is NaCl or Na2SO4. In some embodiments, the peptide includes a positively-charged peptide and a negatively-charged peptide.

[0210] In systems in which the product is excluded from the dense phase, centrifugation causes the droplets to coalesce into one large droplet phase in the pellet, and the excluded product can be collected from the supernatant. The reaction can be initiated again by adding fresh reactants to the pellet and resuspending it to re-form the droplets. Accordingly, in some embodiments, the method further includes a step of collecting the reaction products by centrifugation and collecting the supernatant.

[0211] When the product is in the dense phase (in the condensate), it may be collected by centrifugation and collecting the supernatant. This application may be suitable, for example, for ADC-generating reactions.

[0212] Accordingly, in some embodiments, the method further includes a step, following formation of the products, including centrifugation of the composition to separate the products present in the condensate (the dense phase) from the copper ions, and decanting the copper-containing dilute phase. In some embodiments,, the centrifugation is at about 15,000-20,000 RCF. In some embodiments, the centrifugation is at about 17,000 RCF. In some embodiments, the centrifugation is for about 10-90, 10-60, or 10-30 minutes. In some embodiments, the centrifugation is for about 15-30 minutes. In some embodiments, the centrifugation is for about 10, 15, 20, 25, or 30 minutes.

[0213] Formation of products (including ADCs) may be followed by any suitable method. For example, the reaction may be sampled at certain time intervals and presence of products may be measured by, e.g., high-performance liquid chromatography (HPLC). When a sufficient amount of products has been formed, or when the amount of product reaches a plateau over time, the reaction products may be further processed.

[0214] Following the centrifugation, when the product is a large protein (as in the case of an ADC), the product may be separated from the peptide of the condensate by filtration with a suitable filter cuttof.

[0215] Accordingly, in some embodiments, the method further includes a step, following formation of the products and optionally following the step of centrifugation to separate from the copper salt, including filtering the reagent-containing condensates (or the lower phase / pellet from the centrifugation) to separate the ADCs, which are retained on the filter, from the peptide, which flows through. Nonlimiting filter sizes include 2-100 kDa molecular weight cutoff (MWCO), 2-50 kDa MWCO, 2-20 kDa MWCO, 2, 5, 10, 30, 50, or 100 kDa MWCO. In some embodiments, the filter is a 30 kDa MWCO filter (e.g., Amicon® or Vivaspin®). In some embodiments, the filteris a 10 kDa MWCO filter. In some embodiments, the filter is a 20 kDa MWCO filter. In some embodiments, the filter is a 50 kDa MWCO filter.

[0216] The filters may be centrifuges for about 15-90 minutes at a relative centrifugal force of about 15-19kRCF, or about 17k RCF.

[0217] Following separation of the CuAAC products from the peptide, the peptide may be reused by adding CuAAC reagents (including copper) and repeating the same method.

[0218] Accordingly, in some embodiments, the method further includes a step reusing the peptide-based condensate following the filtering step for isolating the products, by adding to the flow-through an azide-containing compound, an alkyne-containing compound, a copper salt, and optionally a reducing agent.

[0219] In some embodiments, the CuAAC reaction is for preparing ADCs from an mAb and a drug. In some embodiments, the CuAAC reagents are more specifically ADC reagents including an mAb and a drug, as further detailed below. In some embodiments, one of the mAb and the drug is conjugated to the azide-containing compound and the other one of the mAb and the drug is conjugated to the alkyne-containing compound

[0220] In some embodiments, there is provided a method for preparing ADCs by a CuAAC reaction in a peptide-based condensate, the method including:

[0221] a) preparing an aqueous composition including a first and a second ADC reagents in peptide- based condensates in an aqueous buffer by:

[0222] i. combining the peptide, a copper salt, and the first ADC reagent, in the aqueous buffer to form the peptide-based condensate by liquid-liquid phase separation (LLPS), and adding the second ADC reagent to form the aqueous composition; or ii. combining the peptide and the first ADC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second ADC reagent and the copper salt following the LLPS to form the aqueous composition, and b) incubating the composition until ADCs form,

[0223] wherein:

[0224] the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;

[0225] the G in the GX or XG dyad is glycine;

[0226] the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid;the first and the second ADC reagents together include both an mAh and a drug and following LLPS become at least partially encapsulated within the condensate; and

[0227] one of the mAb and the drug is linked to an azide-containing compound and the other one of the mAb and the drug is linked to an alkyne-containing compound.

[0228] Definitions and embodiments mentioned above and which may be relevant to the embodiments in this section also apply here, and vice versa. Some particularly relevant embodiments may be pointed out or explicitly repeated. For terms used herein, unless stated otherwise, their definition and embodiments are intended to be the same as above (mutatis mutandis).

[0229] As indicated above, the terms “combining” and “adding” with respect to ingredients are not intended to imply that the ingredients are added at the same time, and do not specify the order in which they are added.

[0230] In some embodiments, the azide-containing compound is linked to an mAb and the alkyne-containing compound is linked to a drug. In some embodiments, the azide-containing compound is linked to a drug and the alkyne-containing compound is linked to an mAb.

[0231] The method may further includes steps and features indicated above for the CuAAC reaction, such as adding a reducing agent, types of suitable copper salts, etc. Some of the embodiments are also reiterated below.

[0232] In some embodiments, Item a(ii) further includes combining with the peptide and first reagent a phase separation salt that is not a copper salt to facilitate LLPS. In some embodiments, the phase separation salt is selected from sodium salt, potassium salt, magnesium salt, calcium salt, zinc salt, manganese salt, iron salt, cobalt salt, and nickel salt. In some embodiments, the sodium salt is NaCl or Na2SO4. In some embodiments, the peptide includes a positively-charged peptide and a negatively-charged peptide.

[0233] In some embodiments, the method further includes a step, following formation of the ADCs, including centrifugation of the composition to separate the products present in the condensate (the dense phase) from the copper ions, and decanting the copper-containing dilute phase. Parameters of the centrifugation may be the same as indicated above.

[0234] In some embodiments, the method further includes a step, following formation of the products and optionally following the step of centrifugation to separate from the copper salt, including filtering the reagent-containing condensates (or the pellet from the centrifugation) to separate the ADCs, which are retained on the filter, from the peptide, which flows through. Filter sizes may be the same as indicated above. Also methods for following product formation (ADC formation) are indicated above.As detailed above, following filtration the peptide in the flow-through may be reused by adding fresh reagents.

[0235] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.

[0236] The term "a" and "an" refers to one or to more than one (i.e., to at least one, or to one or more) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0237] The term "about", when referring to a measurable value such as an amount, a ratio, and the like, is meant to encompass variations of ±10% of the indicated value, as such variations are also suitable to perform the disclosed invention. Any numerical values appearing in the application are intended to be construed as if preceded by “about”, unless indicated otherwise.

[0238] While certain embodiments of the invention have been illustrated and described, it will be clear that the invention is not limited to the embodiments described herein. Numerous modifications, changes, variations, substitutions, and equivalents will be apparent to those skilled in the art without departing from the spirit and scope of the present invention as described by the claims, which follow.

[0239] The following examples are presented in order to more fully illustrate some embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

[0240] EXAMPLES

[0241] Materials and Methods

[0242] Materials and reagents

[0243] Peptides were custom synthesized and purified by GenScript (Hong Kong). 4-Ethynyl anisole, Rhodamine B, t-BtOH and sodium sulfate (NaSO4), manufactured by ACROS organics; AHC by Apollo Scientific, copper sulfate (Q1SO4) by Fisher Bioreagents; Sodium ascorbate (NaAsc) by G1 entham Life Sciences; Copper (ii) chloride dihydrate (Q1Q2 2H2O) by combi blocks; 7-Hydroxycoumarine (coumarin) by Aaron Chemical; acetonitrile (ACN) by biolab. Buffer salts: sodium citrate by Chem-Impex International, citric acid by Alfa Aesar and MES by Glentham Life Sciences.Peptide solution preparation

[0244] All peptide condensates were prepared as follows: The desired peptide was dissolved in 20 mM citrate / MES buffer pH=6 at a final concentration of 5, 10, or 20 mM (final pH=5.5). In MES buffer, the pH was adjusted to 5.7 or 7.5. Condensates were formed following the addition of 10 mM CuSO4.

[0245] Phase diagrams

[0246] Condensates were prepared by mixing a stock solution of peptide (final concentration of 2.5, 5, and 10 mM) dissolved in 20 mM citrate buffer pH 6 with 2% (v / v%) of CuSO4 dissolved in DDW (solution B) to a final concentration of 2.5, 5 and 10 mM. Condensates were formed immediately upon mixing. All measurements were performed at room temperature. Turbidity was measured in triplicates by an optical density at k=400 nm in a BioTek Hl synergy plate reader using 384-well plate. A bright field imaging was taken for samples at reported concentrations by fluorescence microscope (Olympus 1X83), x40 / 0.95 NA Universal Plan Extended Apochromat objective. Images were collected and processed using Cell Sens Dimension software.

[0247] FRAP analysis

[0248] Fluorescence recovery after photobleaching (FRAP) experiments were performed using a Zeiss 900 LSM confocal microscope by tracking the fluorescent signal of 10 pM rhodamine B as payload. All the solutions were imaged on a slide coated by a solution of Pluronic F-127 surfactant, dissolved in DDW at a concentration of 10 mg / ml. Photobleaching was performed to a circular area with a diameter of 1.2 pm using 17 iterations of Xex = 488 nm laser at 100% intensity, and subsequent recovery of the fluorescence at the bleached area was recorded and analyzed Zen Blue 3.2 software. Photobleaching correction and recovery time were calculated using OriginLab 9.95. Each experiment was normalized between 0% (bleach intensity) and 100% (intensity before bleaching). Then, the normalized data was fitted to the next equation to extract the fitting parameters: y = a — bcx, when a is the recovery that was measured, ti / 2 values of WGI-0 and WGI-1 were calculated for each experiment using a,b,c extracted from the fitting, with the following equation: t = logcThe final FRAP recovery curve is the average of recovery

[0249]

[0250] curves collected from n=4-8 separate condensates.Product synthesis and purification

[0251] A mixture of 4-ethynylanisole (100 mg, 109 pL) and AHC (152.4 mg) in DMF (2 mL) was prepared. To this solution, CuSO4 (188 mg) dissolved in 1 mL of DDW and NaAsc (223 mg) dissolved in 1 mL of DDW were added sequentially. The reaction was stirred overnight under an argon atmosphere. Upon completion, the reaction mixture was quenched with DDW and extracted three times with ethyl acetate. The organic layer was concentrated under reduced pressure to afford the crude product. Yield: 83%. H1NMR (400 MHz, DMSO) 88.89 (s, 1H), 8.63 (s, 1H), 7.88 (d, 2H), 7.76 (d, 1H), 7.05 (d, 2H), 6.91 (d, 1H), 6.88 (s, 1H), 3.81 (s, 3H). LCMS: 336.31 [M+H]+.

[0252] Product calibration curve

[0253] Product was dissolved at 1 mM stock solution in ACN. Then, diluted with ACN to 0.2, 0.4, 0.5, 0.6, 0.8 mM. all solutions were diluted once more with 5% t-BtOH (%v / v) in DDW (ratio 1:1), to compare the kinetics injection conditions. The product was monitored by high-performance liquid chromatography (HPLC), analytical reverse-phase (RP)-HPLC, Thermo Fisher), a Dionex SD Ultimate 3000 UHPLC standard system equipped with a diode-array detection (DAD) detector. Mobile phases were (A) H2O (0.1% trifluoroacetic acid; TFA) and (B) MeCN (0.1% TFA), stationary phase was CS chromatography MultoHigh C18 column (250 mm x 4.6 mm, 5 pm particle size and 100 A pore size, 5861272). Gradient: 35% to 40% solvent B in 24 minutes at flow rate of 1 mL / min. Area of the peak was analyzed at absorption of 214 nm, retention time: 20.3 minutes.

[0254] AHC calibration curve

[0255] 3-azido-7-hydroxy coumarin (AHC) was dissolved in a stock solution of 20 mM in t-BtOH. From this solution, a serial dilution was made for the following stock solutions: 16, 12, 10, 8, 6, 4, 2 mM. From each stock solution, 5 pL were diluted in 95 pL DDW to final concentrations: 1, 0.8, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 mM, then 100 pL ACN was added to compare to the kinetics conditions. AHC was monitored by HPLC, Gradient: 35% to 40% solvent B in 24 minutes at flow rate of 1 mL / min. Area of the peak was analyzed at absorption of 214 nm, retention time: 11.7 minutes.

[0256] Coumarin calibration curve

[0257] Coumarin was dissolved in a stock solution of 10 mM in tert-butanol. This solution was diluted in DDW and tert-butanol, to the following concentration: 0.5, 0.4, 0.3, 0.2,0.1 mM, while tert butanol was kept at a final concentration of 5% v / v. this solution was further diluted with ACN (1:1). coumarin was monitored by HPLC, Gradient: 35% to 40% solvent B in 24 minutes at flowrate of 1 mL / min. Area of the peak was analyzed at absorption of 214 nm, retention time: 8 minutes.

[0258] Preparation of reactions in condensates

[0259] Peptide solutions were prepared as described above. AHC and 4-Ethynylanisole (both reactants were dissolved in 10 mM t-BtOH) were added to peptide solution at a final concentration of 0.5 mM. NaAsc (stock solution IM in DDW) was added at a final concentration of 20 mM. Then, CuSCU (stock solution IM in DDW) was added at a final concentration of 10 mM, following incubation of 30 minutes in argon. Condensates were formed immediately upon addition of CuSO4.

[0260] Reaction kinetics HPLC analysis

[0261] For each condensate system, ACN was added at a final volume percentage of 50% v / v to quench the reaction at the desired time point (0, 5, 10, 15, 20, 40, 60, 80, 100 minutes). Product formation was monitored over time using HPLC. Gradient: 35% to 40% solvent B in 24 minutes at flow rate of 1 mL / min. Analysis was at X=214 nm to monitor the reactants / product. Data points represent averages of at least three independent measurements. Statistical test used to compare the reactions rates was 2-sided t-test.

[0262] Encapsulation efficiency (EE) analysis

[0263] i . F or Cu A AC reach on

[0264] Peptides were dissolved at 10 mM in buffer as previously described, unless otherwise specified. Then the following solutions was added: 10 mM AHC / coumarin in t-BtOH (final concentration of 0.5 mM), DDW (2%, v / v%), and CuSCh / NaSCh / CuCb dissolved in 1 M in DDW (final concentration 10 mM). Droplets were formed when CuSCh / NaSCh / CuCb was added. Then, the droplet solutions were centrifuge at 20°C, in 17K RCF (relative centrifugal force) for 30 minutes. 100 pL from the supernatant were diluted with 100 pL ACN. AHC / coumarin was monitored by HPLC, Gradient: 35% to 40% solvent B in 24 minutes at flow rate of 1 mL / min. Peak area was analyzed at A=2 I 4 nm, AHC retention time: 11.7 minutes, coumarin retention time: 8 minutes. Concentration in supernatant was calculated using calibration curves. %EE was (C'—C \

[0265]

[0266] 1csupj x 100. Values are based on 4 independent analyses for 10 mM and 20 mM WGL1 in MES buffer pH 5.7, 6 independent analyses for 10 mM WGI-0 in MES pH 5.7 and all other values are based on 5 independent analyses for each system.ii. For antibody conjugation

[0267] An antibody linked to an azide-containing compound is dissolved in buffer and the peptide is dissolved in the antibody-containing buffer. Then, LLPS is initiated as described above, either by using copper salt or adding a copper salt or other salt and adding the copper salt after condensate formation. In complex coacervation, a negatively charged peptide (e.g., including acidic residues such as those of glutamic or aspartic acid) is added to a positively charged peptide (e.g., including basic residues such as those of arginine or lysine) to initiate liquid-liquid phase separation (LLPS). In simple coacervation systems, salt e.g. NaCl is added to initiated LLPS instead of a copper salt. A cytotoxic drug linked to alkyne-containing compound is added to the preformed peptide condensate solution. EE analysis is obtained by measuring the antibody and drug concentration in dilute phase following centrifugation and using appropriate calibration curves.

[0268] Confocal microscopy analysis of reaction kinetics

[0269] For each condensate system, condensates sample with reaction was prepared as described above. 35 pl of the reaction were transferred to a coated 96-well plate (coated with 100 pl of Pluronic F-127 surfactant). The solution was imaged using a Zeiss LSM 900 inverted confocal microscope, using an ke=405 nm laser, and collection emission range of Aem= 410-700 nm. Images were taken over time, for 20 minutes. The collected images were taken using z-stack mode. Condensates of each sample were analyzed using the Zen blue 3.2 software (Zeiss) software to show the average fluorescence in condensates over time, and background fluorescence over time.

[0270] 5 mM WGI-1 in citrate buffer: at 0 mins n=23, 10 mins n=53, 20 mins n=20; 5 mM WGL0 in citrate buffer: at 0 mins n=30, 10 mins n=32, 20 mins n=34. 20 mM WGLl in MES buffer: at 0 mins n=30, 10 mins n=35, 20 mins n=25; 20 mM WG0-1 in MES buffer: at 0 mins n=22, 10 mins n=33, 20 mins n=21.

[0271] Example 1: Design of peptide condensates with varying hydrophobicity

[0272] Biomolecular condensates were developed, that function as reaction vessels and facilitate the spatial modulation of chemical transformations. The starting point was a 14-mer peptide designed to promote LLPS via simple coacervation, forming biomolecular condensates (Baruch Leshem, A. et al. Biomolecular condensates formed by designer minimalistic peptides. Nat. Commun. 14, 421 (2023). Examples for such peptides include: WGRGRGRGWPGVGY (also termed herein WGI-0, SEQ ID NO: 1); WGRGRGRGWPGVGF (SEQ ID NO: 2);

[0273] WGRGRGRGWY (SEQ ID NO: 3); WGRGRGWPGVGY (SEQ ID NO: 4);

[0274] WGRGRGRGWQGVGY (SEQ ID NO: 5); and WGRGRGRWY (SEQ ID NO: 6)), as well asthe same peptides having the arginines (R) substituted with glutamic acids (E), WGEGEGEGWPGVGY (WGE, SEQ ID NO: 7), WGEGEGEGWPGVGF (SEQ ID NO: 8), WGEGEGEGWY (SEQ ID NO: 9), WGEGEGWPGVGY (SEQ ID NO: 10), WGEGEGEGWQGVGY (SEQ ID NO: 11); and WGEGEGEWY (SEQ ID NO: 12). The peptide sequence includes three repeats of glycine-arginine (Gly-Arg, GR) or glycine-glutamic acid (Gly-Glu, GE) dyads, which are common in low-complexity domains of IDPs and promote phase separation by providing backbone flexibility. Additionally, the peptide includes three aromatic amino acids-two tryptophans (Trp) and one tyrosine (Tyr)-which drive TI-TI interactions among themselves and with the Arg side chains. To further enhance LLPS, the peptide may incorporate an elastin-like polypeptide domain (Pro-Gly-Val-Gly, SEQ ID NO: 13), known to promote phase separation through simple coacervation. To investigate how condensate properties, particularly hydrophobicity, influence reaction conversion, a small library of peptide building blocks with varying hydrophobicity was designed by introducing different numbers of the aliphatic amino acid isoleucine (He). WGI-0, the primary peptide (lacking He, WGRGRGRGWPGVGY, SEQ ID NO:

[0275] 1), includes a single aliphatic residue (Vai). Modified peptides with one or two lie residues were designated WGL1 (WGIGRGRGWPGVGY, SEQ ID NO: 14), including two aliphatic residues (I, V), and WGL2 (WGIGRIRGWPGVGY (SEQ ID NO: 15)), including three aliphatic residues (I, I, V), respectively (Fig. 1A). The corresponding peptides having R replaced with E are WGIGEGEGWPGVGY (SEQ ID NO: 16) and WGIGEIEGWPGVGY (SEQ ID NO: 17), respectively.

[0276] CuAAC reactions are well characterized and widely used in drug discovery and proteomic studies, making them an ideal model for studying compartmentalized drug synthesis. Therefore, a CuAAC reaction, namely: Cu(I)-catalyzed reaction between an azide group and a terminal alkyne to form a 1,2, 3 -triazole (Fig. 1A) was used with the condensate system. Since the reaction requires Cu(I) as a catalyst, CuSO4, was used, since it acts both as a catalyst and an initiator of LLPS by screening the charges of the cationic peptides, thereby promoting intermolecular interactions and simple coacervation. First, the LLPS propensity of each peptide as a function of peptide composition and CuSCU concentration at pH 5.5 was evaluated. Peptides were dissolved in citrate buffer at pH 6, which decreases to 5.5 after dissolution, at final concentrations of 2.5 mM, 5 mM or 10 mM. Phase diagrams were constructed by measuring sample turbidity (k=400 nm), following addition of CuSCU, as light scattering by condensates corresponds to turbidity (Fig. IB).

[0277] Microscopy analysis confirmed that the turbidity resulted from condensate formation rather than aggregate formation (Fig. 1C). For WGLO and WGI-1, the addition of CuSCU triggers phase separation and condensate formation (not shown). In contrast, WGL2, above 5 mM, undergoesLLPS immediately when dissolved in buffer (not shown). This indicates that the higher hydrophobicity of WGI-2 promotes attractive forces which overcome the electrostatic repulsion between the peptide molecules, resulting in LLPS and condensate formation.

[0278] These turbidity and microscopy analyses revealed that the LLPS propensity of all three peptides was concentration dependent, with turbidity increasing as a function of peptide concentration. Notably, hydrophobicity played a key role, as evidenced by differences in phase diagram boundaries and turbidity intensity between peptides. Increasing the number of He residues from two (WGI-1) to three (WGI-2) further shifted the phase diagram, enabling LLPS at a lower peptide concentration of 2.5 mM for WGI-2 (Figs. 1B-1C). These results establish a clear correlation between peptide hydrophobicity and LLPS propensity.

[0279] Example 2: Regulation of reactant recruitment to the condensates

[0280] To investigate how the chemical environment of peptide condensates modulates reactant recruitment, the CuAAC reaction between 3 -azido-7-hydroxy coumarin (AHC) and 4-ethynylanisole was selected as a model system. This transformation results in a fluorescent product (kex = 330 nm, kern = 460). The encapsulation efficiency (EE) of AHC in the condensates was evaluated by analyzing AHC concentration in supernatants following centrifugation, using HPLC, calibrated against standard AHC curves.

[0281] In citrate buffer (pH 5.4), the EE for condensates formed by 5 mM WGLO, WGI-1, and WGI-2 was low (7.2±5.5%, 35.8± 3.1%, and 27.7 ± 1.7, respectively), see Figs. 2A and 2B. The low EE in 5 mM WGI-O condensates formed in citrate buffer suggests that the reaction occurs entirely in the dilute phase (not in the condensate). Conversely, the higher EE in 5 mM WGLl condensates implies reactions occur in both dilute and dense phases, contributing to higher conversion. Increasing the peptide concentration to 10 and 20 mM further enhanced AHC recruitment, yielding EE values of up to 43.0 ± 6.7% (WGI-0), 65.1 ± 7.5% (WGI-l), and 69.4 ± 9.7 (WGI-2) (Figs. 2A-2B).

[0282] Replacing citrate with 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 5.7), which binds Cu(IEI) more weakly, enhanced the EE in both WGI-0 and WGI-l condensates. At a peptide concentration of 20 mM, EE reached its highest levels, with 63.7 ± 2.6% for WGI-0 (Fig. 2C) and 91.6 ± 1.6% for WGI-l (Fig. 2D).

[0283] To determine whether Cu2+ions limit reactant recruitment, CuSCU was replaced with Na2SO4 or CuCh in the WGI-0 condensates. These substitutions yielded EE values of 7.9 ± 9.0% and 18.1 ± 9.0%, respectively, indicating that the counterions do not significantly restrict encapsulation (Fig. 2E).To determine whether electrostatic repulsion of the reactant from the cationic peptide was a factor, the EE of AHC with was compared that of coumarin. Surprisingly, the neutral compound coumarin lacking an azide moiety showed even lower EE than AHC (Fig. 2F), suggesting that electrostatic repulsion does not account for the differences in recruitment.

[0284] Example 3: Phase separating peptide systems enhance reaction conversion

[0285] To analyze the impact of phase separated systems on reaction conversion and rate, the Cu(I)-catalyzed CuAAC reaction between 3 -azido-7-hydroxy coumarin (AHC) and 4-ethynylanisole was utilized to form the fluorescent triazole product 7-hydroxy-3-(4-(4-methoxyphenyl)-lH-l,2,3-triazol-l-yl)-2H-chromen-2-one (Xex=330 nm, kCm=460, not shown). The reaction involves the reduction of Cu(II) to Cu(I) by sodium ascorbate (NaAsc), which activates the ethynyl group, allowing azide to form the triazole ring. To prevent oxidation of Cu(I) to Cu(II) reactions were conducted under an argon (Ar) atmosphere. Reactants were used at final concentration of 0.5 mM, as higher concentrations destabilize the condensates during the reaction (not shown).

[0286] Peptides were dissolved in citrate buffer at a final concentration of 5 mM with 10 mM CuSO4, followed by the addition of reactants and NaAsc. Reactants were dissolved in tert-butanol (t-BtOH), where all reactions contained a final concentration of 5% of the solvent. The peptide and reactant solutions were incubated with NaAsc under Ar for 30 minutes before the addition of CuSO4 at a final concentration of 10 mM. Reaction kinetics were monitored using HPLC by measuring product formation over time. Reactions were quenched at specific intervals with acetonitrile (ACN) before injection, thus this analysis represents product formation in the heterogenous mixture of both the dilute and dense phases. The reaction rate was 6-fold faster for WGI-0, ~8-fold for WGI-1, and ~7-fold for WGI-2, than that in bulk buffer, where no significant difference in rate was found between the peptides. (Figs. 3A-3B).

[0287] Brightfield microscopy confirmed that WGI-0 and WGI-1 condensates remained stable throughout the reaction, while WGI-2 condensates aggregated over time (Fig. 3C). Further analysis revealed that WGI-2 aggregation was product-induced as no such aggregation was observed with NaAsc or the reactants alone, potentially explaining its lower conversion. When reactions were conducted at a peptide concentration of 2mM, which is below the saturation concentration (Csat), where no condensates form, the conversion rates for WGI-0 and WGI-1 peptides were similar to those in buffer, highlighting the role of the dense phase in enhancing reaction efficiency (Fig. 3D-3E).

[0288] The lower reaction conversion in citrate buffer suggests that citric acid ions inhibit the reaction, possibly by acting as ligands to Cu(II) / Cu(I) and competing with its interaction with theethynyl group. Since citrate buffer facilitates phase separation through charge screening, it is plausible that in the WGI-0 and WGI-1 systems, citric acid ions interact preferentially within the dense phase rather than binding to Cu(II) / Cu(I). This interaction may mitigate the inhibitory effect of citric acid ions, resulting in higher conversions in these systems. However, the significantly higher conversion observed in the WGI-1 system compared to DDW suggests that the dense phase provides additional functionality beyond merely sequestering citric acid ions.

[0289] Performing the reactions in condensates formed in MES buffer at a higher peptide concentration (20 mM) increased the reaction rate by 3.5-fold and 2-fold in WGI-0 and WGI-1, respectively, compared to bulk buffer solution and 4.5-fold and 2-fold by WGI-0 and WGI-1, respectively, compared to DDW (Figs. 3F-3G). Similarly, the condensates exhibited a faster coalescence compared to those in citrate buffer at a lower peptide concentration (not shown).

[0290] To investigate the localization of the fluorescent product over reaction time in LLPS systems, confocal laser scanning microscopy (CLSM) analysis was performed in citrate and MES buffers. CLSM imaging revealed that for all peptide systems in both citrate and MES buffers, the fluorescent product accumulated preferentially within the condensates, with over 90% of the total signal localized in the dense phase (Figs. 3H-3I).

[0291] Example 4: The diffusion in the condensates correlates with peptide hydrophobicity

[0292] To assess whether the material properties of the condensates influence the observed reaction rates, fluorescence recovery after photobleaching (FRAP) analysis of rhodamine B-loaded condensates formed in citrate buffer using CLSM was performed. Diffusion of rhodamine B within the dense phase provides insight into condensate dynamics.

[0293] After photobleaching of the dye which is inside the condensate, the black spot generated by the bleaching is followed with time to see if it remains constant, meaning that the condensate is solid and not dynamic, or diffuses, meaning that the condensate is dynamic. Condensates were formed by 10 mM peptide concentration. The results demonstrate that peptide hydrophobicity significantly impacts condensate dynamics (Fig. 4A-4I).

[0294] The EE of rhodamine B in WGLO, WGI-1, and WGI-2 condensates was first assessed. Condensates were prepared with a 10 mM peptide concentration, as the 5 mM peptide yielded condensates that were too small or dynamic for reliable CLSM analysis. EE values, obtained by absorbance spectroscopy of the dilute phase following condensate centrifugation and using calibrated rhodamine B, were 97%, 90%, and 94% for WGLO, WGI-1, and WGI-2, respectively (Fig. 4A). For WGI-2, which also forms condensates without CuSO4, the EE in the absence of CuSO4 was 99%, indicating that CuSO4 slightly restricts rhodamine B recruitment.FRAP analysis revealed a marked effect of peptide hydrophobicity on condensate dynamics (Fig. 4B). Increasing the number of He residues in the peptide building block from zero to one (and the number of aliphatic residues from one to two) increased the recovery ti / 2by 2.3-fold (21.5 ± 7.4 s for WGI-0 compared to 48.0 ± 13.3 s for WGI-1. This trend was further supported by a twofold higher total recovery in WGI-0 condensates (79.5±8.3%, Fig. 4C) compared to WGI-1 condensates (38.5±6.7%, Figs. 4D). Further increasing the number of He residues to two drastically altered the condensate properties, as WGI-2 condensates exhibited no fluorescence recovery after photobleaching (Fig. 4E). In the absence of CuSO4, however, WGI-2 condensates recovered with H / 2 = 35.8 ± 6.7 s (Fig. 4F), suggesting that CuSO4 attenuates diffusion. Notably, the presence of the salt seems to decrease the fluorescence intensity (Fig. 41). The reduced dynamics of WGI-2 condensates are consistent with their propensity to aggregate during the reaction course.

[0295] As shown in Figs. 2C-2D, MES buffer at a higher peptide concentration (20 mM) results in AHC partitioning mainly into the dense phase, suggesting that the reaction occurs in the dense phase and pointing to a direct relationship between diffusion and reaction rate. Hence, the diffusion of fluorescein in WGI-0 and WGI-1 condensates (20 mM) in MES buffer was analyzed. The 2.3-fold faster reaction rate observed in WGI-0 compared to WGI-1 condensates (Fig. 3G) is consistent with the ~2.6-fold slower diffusion (tl / 2) and 1.5-fold lower total recovery in WGI-1 condensates (Figs. 4G-4H).

[0296] Example 5: Cu2+localization in peptide condensates

[0297] To investigate the localization of Cu2+ions within the peptide condensates, scanning transmission electron microscopy (STEM) coupled with energy dispersive spectroscopy (EDS) was performed on WGI-0 (Figs. 5A-5B), WGI-1 (Figs. 5C-5D), and WGI-2 (Figs. 5E-5F) condensates in citrate buffer. High-angle annular dark-field (HAADF) imaging combined with EDS line profiling revealed the presence of Cu2+ions within the dense phase of all three condensates. Quantitative comparison of the net Cu signal showed that the highest level of accumulation of Cu2+occurs in the most hydrophobic condensates formed by WGI-2. This enhanced Cu2+retention correlates with the markedly reduced internal mobility observed for WGI-2 condensates in the FRAP analysis.

[0298] To test whether Cu2+ions could be effectively removed by simple post-condensation processing, the concentration of Cu2+ions remaining in the supernatant after centrifugation (such as about 15-30 min at 17k RCF) of the condensates (initially including 10 mM CuSOQ were quantified, using both inductively coupled plasma mass spectrometry (ICP-MS) and absorptionspectroscopy (X=750 nm). In both methods, quantification was based on standard calibration curves for Cu2+. ICP-MS analysis indicated complete exclusion of Cu2+ions from the condensate pellet, corresponding to the droplets (Fig. 5G), since about 10 mM of Cu+2ions was detected in the supernatant (corresponding to the dilute phase), while absorption spectroscopy showed that approximately 71%, 86%, and 81% of the Cu2+ions were removed from the supernatant following centrifugation of WGI-0, WGI-1, and WGI-2 condensates, respectively (Fig. 5H). These results suggest that Cu2+sequestration within the condensates is reversible and that a significant fraction can be removed through straightforward processing steps, potentially reducing toxicity concerns in downstream applications.

[0299] Example 6: Application of the condensate system for preparing antibody-drug conjugates (ADC)s

[0300] The ADC preparation workflow is generally described in Fig. 6, and includes combining reagents including a monoclonal antibody (mAb) (linked to azide), a drug (linked to alkyne), and a reducing agent such as sodium ascorbate with the aqueous composition described above. CuSO4 is added to the aqueous composition to trigger phase separation and condensate formation either before, together with, or after adding the reagents (Fig.6 top). The CuSO4 also initiates the CuAAC reaction. After the reaction is complete (e.g. by measuring no change in product quantities by HPLC), a brief centrifugation (such as 15 min at 17kRCF) is conducted to separate the Cu-containing supernatant from the peptide-rich pellet that contains the ADC (Fig.6 right). This pellet is then processed via centrifugal filtration (e.g., 30 kDa Amicon® or Vivaspin®), allowing small peptides (-1500-1800 Da) to pass through while retaining the >152 kDa ADC (Fig. 6 bottom). The peptide-rich filtrate can be reused by simply replenishing it with fresh reagents (Fig. 6 left), thereby enabling a sustainable and modular synthesis cycle.

[0301] The peptide condensate system is tested using the antibody cetuximab, a chimeric human / mouse IgGl monoclonal antibody targeting epidermal growth factor receptor (EGFR), approved for treating colorectal and head-and-neck cancers. Cetuximab inhibits EGFR signaling, promotes receptor degradation, and engages immune mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and dendritic cell-mediated antigen presentation. The cetuximab may be functionalized by linking to UDP-N-azidoacetylgalactosamine (UDP-GalNAz).

[0302] Three clinically relevant, alkyne-functionalized, cytotoxic drugs are used for conjugating to cetuximab for preparing an ADC: (i) monomethyl auristatin E (MMAE), an antimitotic agent blocking tubulin polymerization; (ii) monomethyl auristatin F (MMAF) which is also anantimitotic agent blocking tubulin polymerization; and (iii) SN-38 (7-ethyl-10-hydroxycamptothecin, a metabolite of irinotecan), a topoisomerase I inhibitor antineoplastic drug.

[0303] For site-specific azide labeling of cetuximab, several known methods may be used, such as lysine or cysteine conjugation.

[0304] To quantify EE of the reactants (drug and antibody) by the condensates, cetuximab is labeled with fluorescent dyes and analyzed by both CLSM and absorbance spectroscopy. Since MMAE, MMAF, and irinotecan are small, hydrophobic molecules and contain aromatic groups, fluorescent labeling may cause artifacts. Therefore, EE of these drugs is analyzed by HPLC using predetermined calibration curves for each compound. Finally, the ability of condensates to support diffusion is assessed by FRAP (fluorescence recovery after photobleaching) experiments using fluorescently labeled peptides.

[0305] MMAE and MMAF, being hydrophobic pentapeptides, are predicted to partition efficiently into the dense phase. Similarly, SN-38 (logP ~2.6-3.0) is expected to be sequestered within the condensates based on our prior encapsulation studies using similar hydrophobic azide-functionalized molecules (e.g., AHC).

[0306] Figs. 7A-7D demonstrate a proof of concept for antibody encapsulation by the condensates by showing successful encapsulation of three different monoclonal antibodies (rituximab, bevacizumab (Avastin®), and infliximab) in the condensate. As shown, peptide condensates formed by combination of two LLPS-promoting peptides, WGI-0 and WGE, undergo LLPS into condensates that efficiently recruit mAbs, as analyzed by both absorbance spectroscopy (Fig. 7A) and confocal laser scanning microscopy (Figs. 7B-7D) using fluorescently labeled antibodies. The absorbance spectroscopy analysis of the antibodies EE was obtained by monitoring the absorbance of the Alexafluor640 labeled antibodies in the supernatant following centrifugation and using a calibration curve for each labeled antibody, as detailed above.

[0307] Once encapsulation efficiency and molecular diffusivity are confirmed, CuAAC reactions between UDP-GalNAz-functionalized cetuximab and each of the three alkyne-containing cytotoxic drugs are conducted. To maximize reaction efficiency, several key parameters are systematically optimized: copper salt concentration, reducing agent concentration, ligand-to-copper ratio, overall reactant concentrations and stoichiometries, and the minimal concentration of peptide building blocks required to form condensates with the desired physicochemical properties. Reaction kinetics and product yield, defined as the rate and extent of ADC formation — are monitored using analytical methods including size exclusion chromatography (SEC -HPLC), hydrophobic interaction chromatography (HIC), and liquid chromatography-mass spectrometry (LC-MS) for precise DAR quantification. These outcomes are compared to alternativebioconjugation strategies such as copper-free CuAAC reaction and traditional NHS ester or maleimide-thiol coupling methods.

[0308] Following ADC isolation, EGFR binding activity of the cetuximab conjugate is evaluated. The evaluation is done by an enzyme linked immunosorbent assay (ELISA) using recombinant human EGFR protein and comparing ADC binding to that of unconjugated cetuximab. Additionally, FACS analysis is conducted using HCT116 colorectal carcinoma cells as an EGFR+ model. Cetuximab binding is detected with fluorescently labeled secondary antibodies and compared to free cetuximab. EGFR" cells are used as a negative control. In addition, CLSM is used to assess ADC binding to EGFR+cells via fluorescently labeled ADC and secondary antibody. To further validate EGFR recognition in clinically relevant samples, ADC binding is tested in primary tumor-derived lysates from head and neck squamous cell carcinoma (HNSCC) and colorectal adenocarcinoma.

Claims

CLAIMSWhat is claimed is:

1. An aqueous composition comprising a peptide-based condensate in an aqueous buffer, the condensate comprising:a peptide comprising: at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues; andreagents for a CuAAC reaction comprising an azide-containing compound, an alkyne- containing compound, and a copper salt,wherein:the G in the GX or XG dyad is glycine; andthe X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid.

2. The composition of claim 1, wherein the composition comprises less than 10% of an organic solvent.

3. The composition of claim 2, wherein the organic solvent is tert-butanol.

4. The composition of claims 1, wherein the composition does not comprise an organic solvent.

5. The composition of any preceding claim, wherein the aliphatic residues are selected from isoleucine, alanine, leucine, valine, and combinations thereof.

6. The composition of any preceding claim, wherein the peptide comprises 1 or 2 aliphatic residues.

7. The composition of any preceding claim wherein the at least one GX or XG dyad is at least two GX or XG dyads.

8. The composition of any preceding claim, wherein the at least one aromatic amino acid is selected from tryptophan, phenylalanine, tyrosine, and histidine.

9. The composition of any preceding claim, wherein the at least one aromatic amino acid is at least two or at least three aromatic amino acids.

10. The composition of any preceding claim, wherein the peptide comprises an elastin-like polypeptide domain (ELP: Pro-Gly-Val-Gly, SEQ ID NO: 13).

11. The composition of any preceding claim, wherein the peptide comprises a sequence selected from SEQ ID Nos: 1, 14-15, 2-7, 16-17, and 8-1212. The composition of any preceding claim, wherein the peptide is at a concentration of about 2.5-20 mM.

13. The composition of any preceding claim, wherein the aqueous buffer is selected from a 2-(N- morpholino)ethanesulfonic acid (MES) buffer, a citrate buffer, a phosphate buffer, HEPES (4- (2-hy droxy ethyl)- 1 -piperazineethanesulfonic acid), and a Tris buffer.

14. The composition of any preceding claim, wherein the buffer concentration is about 5-50 mM.

15. The composition of any preceding claim, wherein the pH of the composition is about 5-8.

16. The composition of any preceding claim, wherein the azide-containing compound is 3-azido- 7-hy droxy coumarin (AHC).

17. The composition of any preceding claim, wherein the alkyne-containing compound is 4- ethynyl anisole.

18. The composition of any preceding claim, wherein the copper salt is selected from CuSCU, CuCh, copper nitrate, and copper acetate.

19. The composition of any preceding claim, wherein the copper salt is at a concentration of about 100 pM- 50 mM.

20. The composition of any preceding claim, wherein the composition does not comprise a salt in addition to the copper salt.

21. The composition of any preceding claim, further comprising a reducing agent.

22. The composition of claim 21, wherein the reducing agent is sodium ascorbate.

23. The composition of any preceding claim, further comprising a reaction product at least partially encapsulated within the condensate.

24. The composition of any preceding claim, wherein the CuAAC reaction is for preparing an antibody-drug conjugate (ADC); one of the azide-containing compound and the alkyne-containing compound is linked to a monoclonal antibody (mAb); and another one of the azide- containing compound and the alkyne-containing compound is linked to a drug.

25. The composition of claim 24, wherein the mAb is a monoclonal antibody suitable for treating cancer or for cosmetic treatment.

26. The composition of claim 24 or 25, wherein the mAb is selected from cetuximab, panitumumab, rituximab, obinutuzumab, ofatumumab, bevacizumab, infliximab, trastuzumab, pertuzumab, sacituzumab, zolbetuximab, enfortumab, tisotumab, mirvetuximab, inotuzumab, loncastuximab, brentuximab, gemtuzumab, polatuzumab, and belantamab.

27. The composition of any one of claims 24-26, wherein the drug is a drug suitable for treating cancer or for cosmetic treatment.

28. The composition of any one of claims 24-27, wherein the drug is a cytotoxic drug or an immune modulator.

29. The composition of claim 28, wherein the cytotoxic drug is selected from an auristatin (such as monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF)), a maytansinoid, a calicheamicin, a duocarmycin, a pyrrolobenzodiazepine, a camptothecin derivative, a- amanitin, a tubulin inhibitor (such as a tubulysin or an eribulin derivative), an irinotecan or a metabolite thereof (such as 7-ethyl-10-hydroxy camptothecin (SN-38)), and a BCL-XL inhibitor.

30. The composition of any one of claims 24-29, wherein the monoclonal antibody (mAb) and / or the drug are at least 90% encapsulated within the condensate.

31. The composition of any one of claims 24-30, further comprising ADCs at least partially encapsulated within the condensate, wherein at least 70% of the ADCs have a drug-antibody ratio (DAR) which does not vary by more than 1 unit from an average DAR of the ADCs or from a target DAR.

32. A method for conducting a CuAAC reaction in a peptide-based condensate, the method comprising:a) preparing an aqueous composition comprising a first CuAAC reagent and a second CuAAC reagent in peptide-based condensates in an aqueous buffer by:i. combining the peptide, a copper salt, and the first CuAAC reagent, in the aqueous buffer to form the peptide-based condensate by liquid-liquid phase separation (LLPS), and adding the second CuAAC reagent following the LLPS to form the aqueous composition; orii. combining the peptide and the first CuAAC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second CuAAC reagent and the copper salt following the LLPS to form the aqueous composition, and b) incubating the aqueous composition until reaction products form,wherein:the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;the G in the GX or XG dyad is glycine;the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid; andthe first and the second CuAAC reagents together include both an azide-containing compound and an alkyne-containing compound and following LLPS become at least partially encapsulated within the condensate.

33. The method of claim 32, further comprising a step, following formation of the products, comprising centrifugation of the composition to separate the products present in the condensate from the copper ions, and decanting the copper-containing dilute phase.

34. The method of claim 32 or 33, wherein the CuAAC reaction is for preparing an antibody-drug conjugate (ADC); one of the azide-containing compound and the alkyne-containing compound is linked to a monoclonal antibody (mAb); and another one of the azide-containing compound and the alkyne-containing compound is linked to a drug.

35. The method of claim 34, further comprising a step, following formation of the ADCs, comprising filtering the composition to separate the ADCs from the peptide.

36. A method for preparing antibody-drug conjugates (ADC)s by a Copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction in a peptide-based condensate, the method comprising: a) preparing an aqueous composition comprising a first and a second ADC reagents in peptide-based condensates in an aqueous buffer by:i. combining the peptide, a copper salt, and the first ADC reagent, in the aqueous buffer to form the peptide-based condensate by liquid-liquid phase separation (LLPS), and adding the second ADC reagent to form the aqueous composition; or ii. combining the peptide and the first ADC reagent in the aqueous buffer to form the peptide-based condensate by LLPS, and adding the second ADC reagent and the copper salt following the LLPS to form the aqueous composition, andb) incubating the aqueous composition until ADCs form,wherein:the peptide includes at least one GX or XG dyad, at least one aromatic amino acid, and 0-2 aliphatic residues;the G in the GX or XG dyad is glycine;the X in the GX or XG dyad is selected from arginine, lysine, aspartic acid, and glutamic acid; the first and the second ADC reagents together include both a monoclonal antibody (mAb) and a drug and following LLPS become at least partially encapsulated within the condensate; andone of the mAb and the drug is linked to an azide-containing compound and the other one of the mAb and the drug is linked to an alkyne-containing compound.